Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
MDV3100We have completed patient enrollment in a Phase 1-2 clinical trial of our novel, triple-acting oral anti-androgen MDV3100 in patients with metatstatic castration-resistant (also known as hormone refractory) prostate cancer (CRPC), an advanced stage of the disease. To read about MDV3100's mechanism of action and the efficacy and safety results from this trial presented at the ASCO 2009 Annual Meeting, please click here. Click here for Science article. The Phase 3 AFFIRM trial is currently enrolling men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. For more information about our clinical studies, please contact Medivation at This e-mail address is being protected from spambots. You need JavaScript enabled to view it . To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.
|
 |
 |
| Medivation © 2010 |